Investigational Drug Information for Marimastat
✉ Email this page to a colleague
What is the drug development status for Marimastat?
Marimastat is an investigational drug.
There have been 4 clinical trials for Marimastat.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 31st 1997.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Vascular Malformations. The leading clinical trial sponsors are ILEX Oncology Services, Incorporated, National Cancer Institute (NCI), and North Central Cancer Treatment Group.
Summary for Marimastat
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 5,049 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 1,913 |
| Clinical Trial Progress | Phase 3 (1997-01-31) |
| Vendors | 69 |
Recent Clinical Trials for Marimastat
| Title | Sponsor | Phase |
|---|---|---|
| Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options. | Boston Children's Hospital | Phase 1 |
| Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options. | Boston Children’s Hospital | Phase 1 |
| Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy | National Cancer Institute (NCI) | Phase 3 |
Clinical Trial Summary for Marimastat
Top disease conditions for Marimastat
Top clinical trial sponsors for Marimastat
US Patents for Marimastat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
